Author Contributions: Dr Wasko had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Wasko, Hubert, Elliott, Fries, Ward.
Acquisition of data: Wasko, Hubert, Lingala, Luggen, Fries.
Analysis and interpretation of data: Wasko, Hubert, Lingala, Fries, Ward.
Drafting of the manuscript: Wasko, Hubert, Elliott.
Critical revision of the manuscript for important intellectual content: Wasko, Hubert, Lingala, Elliott, Luggen, Fries, Ward.
Statistical analysis: Hubert, Lingala, Ward.
Obtained funding: Wasko, Fries, Ward.
Administrative, technical, or material support: Elliott, Fries.
Study supervision: Wasko, Hubert, Fries, Ward.
Financial Disclosures: Dr Wasko reported being a consultant to Centocor in cardiovascular outcomes in ongoing rheumatoid arthritis clinical trials and has been a coinvestigator in a Merck-sponsored study of thromboembolic markers in rheumatoid arthritis and osteoarthritis. Dr Wasko reported receiving contractual reimbursement as site principal investigator for an Aventis-sponsored clinical trial of leflunomide in rheumatoid arthritis, ending in November 2002. Dr Wasko reported receiving contractual reimbursement as site principal investigator for rheumatoid arthritis clinical trials sponsored by Centocor, Roche, Human Genome Sciences, and Novartis. No other authors reported disclosures.
Funding/Support: This study was conducted with support from the Arthritis Foundation of Western Pennsylvania, the National Arthritis Foundation, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, and the Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health.
Role of the Sponsor: Neither the Arthritis Foundation nor the National Institutes of Health was involved in the design and conduct of the study or in the collection, management, analysis, or interpretation of the data, or the preparation, review, or approval of the manuscript.
Additional Contributions: The authors dedicate this article to the memory of John Sibley, MD, professor of medicine, Royal University Hospital, Saskatoon, Saskatchewan, whose contributions over his 15 years as an ARAMIS investigator were essential to numerous publications based on the ARAMIS cohort prior to his untimely death in 2007. Janice Sabatine, PhD, paid consultant, provided administrative and editorial contributions to the preparation of the manuscript.